Bladder and Urothelial Cancer Treatments

BACKGROUND: No treatment has surpassed platinum-based chemotherapy in improving overall survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma. METHODS: We conducted a phase 3, global, open-label, randomized trial to compare the efficacy and safety of enfortumab vedotin and…

The International Society of Urological Pathology 2012 Consensus Conference made recommendations regarding classification, prognostic factors, staging, and immunohistochemical and molecular assessment of adult renal tumors. Issues relating to prognostic factors were coordinated by a workgroup who identified tumor morp…

• DİLEK BAYDAR

Özet henüz yok.

• MEHMET ÖNER ŞANLI

Özet henüz yok.

• MAHMUT GÜMÜŞ

Özet henüz yok.

• MUSTAFA ÖZGÜROĞLU

Özet henüz yok.

• MELTEM EKENEL

Özet henüz yok.

BACKGROUND: Survival outcomes are poor for patients with metastatic urothelial carcinoma who receive standard, first-line, platinum-based chemotherapy. We assessed the overall survival of patients who received durvalumab (a PD-L1 inhibitor), with or without tremelimumab (a CTLA-4 inhibitor), as a first-line treatment…

BACKGROUND: No new agent has improved overall survival in patients with unresectable or metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy. METHODS: In this phase 3, multinational, open-label trial, we randomly assigned patients with previously untreated unresectable or metastatic ur…

• YÜKSEL ÜRÜN

PURPOSE: There are significant differences in clinicopathological features among renal cell carcinoma histological subtypes but controversy exists regarding the independent impact of histological subtype on patient outcome after nephrectomy. We examined the significance of histological subtype on progression to distan…

• BAYRAM DOĞAN

Özet henüz yok.

• SERDAR TEKGÜL

Özet henüz yok.

• HASAN SERKAN DOĞAN